Researchers have answered many questions about angiogenesis, but many questions still remain. Scientists do not know whether using angiogenesis inhibitors to treat cancer will trigger unknown side effects, how long treatment will need to last, or whether tumor cells will find alternative routes to vascularization. To answer such questions, human clinical trials are currently under way.